Camurus AB

Common Name
Camurus
Country
Sweden
Sector
Healthcare
Industry
Biotechnology
Employees
267
Ticker
CAMX
Exchange
NASDAQ STOCKHOLM AB
Description
Camurus AB is a research-based pharmaceutical company focused on developing and commercializing innovative and effective medicines. The company's primary focus is on addressing significant unmet medic...

Camurus's Financial Statements Preview

Below are the financial statements of Camurus, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in millions of SEK
2024
2023
Total revenue
1,867.58a
1,716.85a
Cost of goods sold
-129.51a
-122.35a
Gross profit
1,738.07a
1,594.5a
Marketing and distribution costs
-492.4a
-375.82a
Administrative expenses
-91.32a
-48.63a
Research and development costs
-683.62a
-637.7a
Other operating income
6.34a
1.06a
Other operating expenses
-7.9a
-7.51a
Operating result
469.17a
525.9a
Financial income
84.44a
24.74a
Financial expenses
-1.08a
-1.34a
Net financial items
83.36a
23.4a
Result before tax
552.52a
549.3a
Income tax
-124.13a
-117.86a
Result for the year
428.39a
431.44a
Download Data

Verified Sources Behind Camurus’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Camurus’s data sources below and access millions more through our Disclosure Search.

a. Camurus's Annual Report 2024
a. Camurus's Annual Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?